EUVIMEDEUVIMED entdecken
Crossref

Comparative pharmacoeconomic analysis of sequential treatment lines for advanced hepatocellular carcinoma: a real-world clinical practice study

N. A. Vlasova, E. V. Eliseeva, V. I. Apanasevich, S. S. Startsev

Сибирский научный медицинский журнал · 21.07.2026 · 46 (3) · 81-91

DOI: 10.18699/ssmj20260308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Сибирский научный медицинский журнал, online erschienen am 21.07.2026. Verfasst von N. A. Vlasova und 3 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim of the study was to conduct a pharmacoeconomic evaluation of different drug therapy regimens for hepatocellular carcinoma (HCC). Material and Methods . This study assessed three treatment strategies for advanced HCC, involving the use of one, two, and three sequential lines of drug therapy. The analysis included the calculation of the Cost- Effectiveness Ratio (CER) and the Incremental Cost-Effectiveness Ratio (ICER). Furthermore, the ICER values were compared against a reference willingness-to-pay (WTP) threshold. The study included 53 patients with unresectable HCC, of whom 37, 13, and 3 received one, two, and three lines of drug therapy, respectively.

Results

The duration of the first, second, and third lines of therapy did not differ significantly. The cost of the first line of therapy was the lowest when compared to the second and third lines. The value of CER was minimal for one line of therapy and maximal for three lines. Overall survival differed significantly only between the groups receiving one and two lines of therapy. The median survival in the groups receiving 1, 2, and 3 lines of therapy was 1.25, 1.83 and 2.0 years, respectively; however, the differences between the 1- and 3-line groups, as well as between the 2- and 3-line groups, were statistically insignificant. The ICER was lowest when comparing one versus two lines of therapy and highest when comparing two versus three lines. In all cases, the ICER exceeded the adopted reference WTP threshold of 2,592,000 RUB/year.

Conclusions

Although strategies involving two and three lines of therapy are associated with a gain in survival, they are characterized by an incremental cost per additional year of life that substantially exceeds the reference WTP threshold. This indicates their limited cost-effectiveness within the adopted evaluation framework. The decision to use these strategies should be made on an individual basis, considering clinical prognostic factors and with an awareness of the substantial financial burden they impose on the healthcare system. These results can be used in funding allocation and drug therapy planning in HCC patients within the domestic healthcare system.

Zitieren

APA

Vlasova, N. A., Eliseeva, E. V., Apanasevich, V. I., & Startsev, S. S. (2026). Comparative pharmacoeconomic analysis of sequential treatment lines for advanced hepatocellular carcinoma: a real-world clinical practice study. Сибирский научный медицинский журнал, 46(3), 81-91. https://doi.org/10.18699/ssmj20260308

Vancouver

Vlasova NA, Eliseeva EV, Apanasevich VI, Startsev SS. Comparative pharmacoeconomic analysis of sequential treatment lines for advanced hepatocellular carcinoma: a real-world clinical practice study. Сибирский научный медицинский журнал. 2026;46(3):81-91. doi:10.18699/ssmj20260308

BibTeX
@article{Vlasova2026,
  author = {Vlasova, N. A. and Eliseeva, E. V. and Apanasevich, V. I. and Startsev, S. S.},
  title = {Comparative pharmacoeconomic analysis of sequential treatment lines for advanced hepatocellular carcinoma: a real-world clinical practice study},
  journal = {Сибирский научный медицинский журнал},
  year = {2026},
  volume = {46},
  number = {3},
  pages = {81--91},
  doi = {10.18699/ssmj20260308}
}
Kostenlos starten →